Bachem’s Collaboration Agreement With Eli Lilly and Company

Wenger Plattner advised Bachem on the deal.

Bachem (SIX: BANB) announced a strategic collaboration with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.

Under this collaboration, Bachem will support the implementation of Lilly’s novel oligonucleotide manufacturing technology with its engineering infrastructure and expertise and provide R&D and production capacity at its Bubendorf (BL) site for the development and manufacture of GMP-grade material for Lilly’s oligonucleotide-based investigational medicines. Manufacturing commitments by Lilly extend over a term of 7 years, with annual order volume potential of around CHF 100m.

The agreement, which stretches across the next seven years, will see the two companies expand current oligonucleotide technologies, develop new oligonucleotide processes and contribute to global manufacturing capacity for oligonucleotide-based medicines for patients.

The Wenger Plattner team was led by Dr. Tobias Meili (Picture).

Involved fees earner: Tobias Meili – Wenger Plattner;

Law Firms: Wenger Plattner;

Clients: Bachem Holding AG;

Federica Tiefenthaler

Author: Federica Tiefenthaler